



## **CURRICULUM VITAE**

**Scott E. Woodman, MD, PHD**

### **PRESENT TITLE AND AFFILIATION**

#### **Primary Appointment**

Associate Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Co-Leader, Pre-Clinical Melanoma Moonshot Program, Moon Shots Program, The University of Texas MD Anderson Cancer Center, Houston, TX

#### **Dual/Joint/Adjunct Appointment**

Associate Professor, Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

### **CITIZENSHIP**

United States

### **EDUCATION**

#### **Degree-Granting Education**

BS, Hillsdale College, Hillsdale, MI, 1993, Philosophy and Biology

MA, Michigan State University, East Lansing, MI, 1996, Philosophy

MS, Albert Einstein College of Medicine, New York, NY, 2000, Biomedical Science

PhD, Albert Einstein College of Medicine, New York, NY, 2004, Molecular Pharmacology

MD, Albert Einstein College of Medicine, New York, NY, 2004, Medicine

#### **Postgraduate Training**

Clinical Fellowship, Internal Medicine, Harvard Medical School, Boston, MA, 7/2004-6/2007

Clinical Residency, Internal Medicine, Beth Israel Deaconess Medical Center, Boston, MA, 7/2004-6/2007

Medical Oncology Fellowship, UT MD Anderson Cancer Center, Houston, TX, 7/2007-6/2010

### **CREDENTIALS**

#### **Board Certification**

American Board of Internal Medicine, 286517, 2007

#### **Licensures**

**Active**

Texas Medical License, TX, M7767, 8/2007-8/2017, renewed (8/2017-8/2027)

**Inactive**

N/A

## **EXPERIENCE/SERVICE**

### **Academic Appointments**

Graduate Research Assistant, Department of Philosophy, Michigan State University, East Lansing, MI, 6/1993-8/1996

Graduate Research Assistant, Department of Molecular Pharmacology, Albert Einstein College of Medicine, New York, NY, 7/1996-6/2000

Instructor, Department of Biology, Yeshiva University, New York City, NY, 6/1998-6/2002

Intern, Beth Israel Deaconess Medical Center/Dana Farber Cancer Institute, Boston, MA, 6/2004-6/2005

Resident, Beth Israel Deaconess Medical Center/Dana Farber Cancer Institute, Boston, MA, 6/2005-6/2007

Chief Resident, Internal Medicine, Beth Israel Deaconess Medical Center/Boston Veterans Administration Hospital, Boston, MA, 9/2006-11/2006

Fellow, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/2007-6/2010

Instructor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2010-6/2011

Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2011-2018

Assistant Professor, Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011-2018

### **Administrative Appointments/Responsibilities**

Director, Melanoma Medical Oncology Grand Rounds (weekly), The University of Texas MD Anderson Cancer Center, Houston, TX, 2011-2017

Interviewer, physician-scientist candidates for the Hematology/Oncology Fellowship program, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - present.

Medical Oncology Fellows, Melanoma Rotation Teaching, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011-present

Melanoma Medical Oncology inpatient attending service (5-8 weeks/year), The University of Texas MD Anderson Cancer Center, Houston, TX, 2011-present

Melanoma Medical Oncology consult pager (1 month/year), The University of Texas MD Anderson Cancer Center, Houston, TX, 2011-present

Co-Leader, Pre-Clinical Program, Melanoma Moonshot, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015-present

### **Other Appointments/Responsibilities**

Graduate Faculty Member, Graduate School of Biomedical Sciences, Houston, TX, 2011-present

Member, Melanoma Research Foundation Breakthrough Consortium, Houston, TX, 2011-present

Leader, Proteomic Analysis and Integration, The Cancer Genome Atlas (TCGA) Network, Cutaneous Melanoma, NCI, NIH/NCI, 2013-2015

Co-chair, The Cancer Genome Atlas (TCGA) Network, Uveal Melanoma, NIH/NCI, 2014-2017

Co-Leader, Pre-Clinical Program, Melanoma Moonshot, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014-present

**Endowed Positions**

N/A

**Consultantships**

Invitrogen  
Life Technologies  
Thermo-Fisher  
Omniseq

**Military or Other Governmental Service**

N/A

**Institutional Committee Activities**

Cardiopulmonary Resuscitation Subcommittee, Member, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008-2011

Clinical Research Committee 4 Subcommittee, Member, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011-2013

Medical Records Committee, Member, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017-present

**HONORS AND AWARDS**

BS (summa cum laude), Hillsdale College, 1993

Donald & Marion Schneider Academic Scholarship, Hillsdale, 1993

University Academic Scholarship, Michigan State University, 1993

Graduate Assistantships, Michigan State University, 1994-1996

MA (summa cum laude), Michigan State University, 1996

Medical Scientist Training Program Grant, National Institutes Health, 1996-2004

MS (Awarded with Distinction), Albert Einstein College of Medicine, 2000

Alpha Omega Alpha Honor Society, Albert Einstein College of Medicine, 2004

Outstanding Resident Teacher Award, Harvard Medical School, Shapiro Institute, 2005-2006

Resident Teaching Award, Harvard Medical School Class of 2007, 2006-2007

NIH T32, Ruth L. Kirschstein National Research Service Award, 2007

Carol Cogdell Courtney Fellowship, Melanoma Oncology, MD Anderson Cancer Center, 2008

Young Investigator Award, Ocular Melanoma Foundation, 2009

ASCO Cancer Foundation Merit Award, American Society for Clinical Oncology, 2009

NIH K12, Paul Calabresi Award for Clinical Oncology, MD Anderson Cancer Center, 2009

ASCO Cancer Foundation Young Investigator Award, American Society of Clinical Oncology, 2009

Achievement in Basic Science Research Award, MD Anderson Cancer Center, 2010

Lupe C. Garcia Fellowship in Cancer Research, MD Anderson Cancer Center, 2010

Advanced Scholar Clinical Oncology Fellowship Grant, Laura and John Arnold Foundation, MD Anderson Cancer Center, 2010-2011

NCI Melanoma SPORE Career Development Award, National Cancer Institute, 2010

National Eye Institute Travel Grant, Association for Research in Vision and Ophthalmology, 2010

Rising STARS Award, University of Texas Systems, 2011-2014

Cancer Center Support Grant Faculty Award, NCI, MD Anderson Cancer Center, 2011-2012

NCI Melanoma SPORE Developmental Research Project Award, 2012-2013

Melanoma Research Alliance, Theodore Popp Jr. Young Investigator Award, 2014-2017

Potu N. Rao Award for Excellence in Basic Science Research (nominee), DoCM, MD Anderson Cancer Center, 2017

## RESEARCH

### GRANTS AND CONTRACTS

#### Funded

Principal Investigator, 20%, Developing Effective Immunotherapeutic Strategies for Advanced Melanoma, RP170317, Individual Investigator Research Award, Cancer Prevention & Research Institute of Texas (CPRIT), 11/16/2016–11/16/2019, \$899,507

Co-Principal Investigator, 4%, Genomics-Guided Discovery of Effective Combination Therapies in Cancer, Innovation in Cancer Informatics Fund Grant, Brown Performance Group, PIs – Woodman, Korkut, 4/1/2017–4/1/2019, \$223,390

Collaborator, 3%, Targeting the Glycolysis Pathway to Overcome Resistance to Cancer Immunotherapy, RP170401, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Patrick Hwu, 12/1/2016-11/30/2019, \$855,000

Principal Investigator, 10%, Institutional Research Grant, Development of Pre-Treatment Determination of Immune Checkpoint Blockade Efficacy in Cancer, MD Anderson Cancer Center, 1/1/2017–1/31/2019, \$75,000

Collaborator, 3%, Phase II Study of Nivolumab in combination with Ipilimumab for Uveal Melanoma, Bristol-Myers Squibb, PI - Sapna Patel, 9/01/2016-8/31/2018.

#### Pending

Co-Principle Investigator, 20%, Targeting Genetic Aberrations in Acral Melanoma, Melanoma Research Alliance Team Science Award, 5/01/2018-4/30/2021, \$900,000

Principal Investigator, 20%, Functional Genomic Interrogation of G-protein Pathways Genes in Cancer, Melanoma Research Foundation, CURE Ocular Melanoma, 5/01/2018–4/30/2019, \$100,000

Co-Principal Investigator, 5%, An Interdisciplinary Approach for Developing Combination Therapies for Metastatic Uveal Melanoma, Emerson Collective Cancer Research Fund, PI - Chandrani Chattopadhyay, 09/01/2018-09/01/2020, \$200,000

Collaborator, 5%, Immunotherapy Selection Through Single Cell Proteomic Profiling of Tumor Cell and Microenvironment, Emerson Collective Cancer Research Fund, PI Anil Korkut, 09/01/2018-09/01/2020, \$200,000

Collaborator, 3%, Comparing the Role of CXCR3 Ligands in Melanoma Immune Responses to Therapy, American Cancer Society (ACS), PI - Larry Kwong, 01/01/2019-01/01/2020, \$792,000.00

Principal Investigator, 20%, The Role of Hallmark Gene Aberrations Associated with Monosomy 2/Chromosome 8q Gain in Uveal Melanoma Immune Evasion and Immunotherapy Resistance, R01, NIH/NCI, \$1,249,950

#### Other

N/A

#### Completed

Co-Principal Investigator, Interrogating the Molecular and Immune Mechanisms of Response/Resistance to Combined KIT Inhibition and CTLA4 Blockade in Melanoma, The University of Texas MD Anderson Cancer Center SPORE in Melanoma – CEP Award, NIH/NCI, co-PI - David Hong, 9/1/2016–8/31/2017, \$79,000

Co-Principal Investigator, Pre-treatment Determination of Immunotherapy Efficacy in Melanoma, NCI P50 (CA093459), Melanoma SPORE Developmental Research Project (DRP) Award, PI - Woodman, Bernatchez, 9/15/2016–8/31/2017, \$25,000

Principal Investigator, Young Investigator Award, Short-Circuiting the Signaling Network in Uveal Melanoma, 14037956, Melanoma Research Alliance, 9/1/2014–9/1/2017, \$225,000

Principal Investigator, Targeting Signaling Aberrations Acral, Mucosal, and Uveal Melanoma, Melanoma Research Alliance, 6/1/2010-5/31/2013, \$100,000

Investigator, Prospective Phase II Study of Dasatinib Treatment in Patients with Acral, Mucosal or Chronic Sun-Damaged Melanoma, K12 CA088084, NIH/NCI, PI - Robert Bast, 9/24/2010-8/31/2015, \$136,080

Principal Investigator, Anne and Don Fizer Foundation Award, Anne and Don Fizer Foundation, 1/27/2014-1/1/2016, \$60,000

Principal Investigator, Rising STARS Award, University of Texas Systems, 9/1/2011-8/31/2014, \$250,000

Principal Investigator, Identification of Unique Gene Expression Sets That Necessitate Uveal Melanoma Gene Mutations and Metastatic Cell Interactions, Melanoma SPORE Developmental Research Project Award, P50 (CA093459), NIH/NCI, 9/15/2012-8/31/2013, \$75,000

Principal Investigator, Determination of the Tyrosine Kinase Mediator(s) and Signaling Mechanisms in Dasatinib Sensitive Melanoma Cells, Bristol-Myers Squibb, 1/1/2013–1/1/2014, \$50,000

Principal Investigator, Faculty Award, NCI Cancer Center Support Grant, NCI P30 (CA016672), NIH/NCI, 6/30/2011–6/30/2012, \$50,000

Co-Principal Investigator, A Phase II Study of Biological Response to Dasatinib Treatment in Patients with Acral Lentiginous, or Mucosal Melanoma, Bristol-Myers Squibb, 5/5/2011 – 5/1/2015, \$385,000

Principal Investigator, Faculty Laboratory Start Up Funds, 01, UT MD Anderson Cancer Center, 7/1/201-present, \$520,000

Principal Investigator, A Systems Biological Approach to Identify Potential Molecular Targets and Therapeutic Response in Uveal Melanoma, NCI (P50 CA093459) Melanoma SPORE Career Development Program Award (Elizabeth A. Grimm), 9/10/2010-8/31/2011 \$25,000

Principal Investigator, A Genetic and Proteomic Analysis of Acral Lentiginous and Mucosal Melanoma Tumors Before versus During Dasatinib Treatment, Institute for Personalized Cancer Treatment, Career Development Award, M. D. Anderson Cancer Center, 9/14/2010-8/31/2011 \$50,000

Principal Investigator, A Determination of the Biological and Clinical Relevance of Kit Gene Alterations in Melanoma, Young Investigator Award, American Society of Clinical Oncology (Patrick Hwu), 06/01/2009-5/30/2011, \$100,000

### **Not Funded**

Co-Principal Investigator, Interrogating the Molecular and Immune Mechanisms of Response/Resistance to Combined KIT Inhibition and CTLA4 Blockade in Melanoma, Elsa U. Pardee Foundations, PI – David S Hong, 12/1/2017-11/30/2018, \$163,719

Principal Investigator, The Role of Hallmark Gene Aberrations Associated with Monosomy 2/Chromosome 8q Gain in Uveal Melanoma Immune Evasion and Immunotherapy Resistance, R01, NIH/NCI, 4/1/2017-3/31/2022, \$1,249,973

Co-Principal Investigator, Interrogating the Molecular and Immune Mechanisms of Response/Resistance to Combined KIT Inhibition and CTLA4 Blockade in Melanoma, RP160245,

Cancer Prevention & Research Institute of Texas (CPRIT), PI - David Hong, 3/1/2016-2/28/2019, \$872,730

Principal Investigator, Identification of Personalized Combinatorial Approaches to Improve Efficacy of Immunotherapy, Cancer Prevention & Research Institute of Texas (CPRIT), High-Impact/High-Risk Research Award, RP160672, 06/01/2016-05/31/2018, \$200,000

Principal Investigator, Development of Pre-Treatment Determination of Immune Checkpoint Blockade Efficacy in Cancer, Cancer Prevention & Research Institute of Texas (CPRIT), Early Translational Research Award, 04/25/2016, \$300,000

Co-Principal Investigator, Developing Therapeutic Approaches for Uveal Melanoma, NCI Melanoma SPORE Project 4. 2016. 2 P50 CA093459-11A1 \$303,954

Collaborator, Dormancy of metastatic uveal melanoma and response to targeted therapies, Melanoma Research Foundation, PI - Andrew Aplin, 10/1/2015-9/30/2017, \$125,000

Principal Investigator, Targeting Critical Molecular Effectors of Aberrant *BAP1* in Cancer, Sidney Kimmel Foundation for Cancer Research, 12/04/2013, \$200,000

Principal Investigator, Determining the Molecular Mechanisms of Mutant G-Protein Alpha Subunit Cancer, Burrows Welcome Fund, 9/1/2011-8/31/2016, \$700,000

Co-Investigator, Quantitative Analysis of Oncogenic G-protein Signaling in Cancer, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Allan R. Brasier, 5/1/2011-4/30/2016

## Protocols

### Funded

Collaborator, Gene Expression Profiling and Molecular Classification of Human Melanoma, LAB01-448, PI - Jeffrey Gershenwald, MD, 2001-present, Melanoma Research Alliance

Collaborator, Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients with Metastatic Melanoma., 2004-0069, PI - Patrick Hwu, MD, 2006, MDACC, NCI, Prometheus Laboratories, Melanoma Research Alliance, Adelson Medical Research Foundation

Collaborator, Blood and Tumor Sample Collection from Patients with Uveal Melanoma, LAB07-0262, PI - Bitu Esmali, MD, 2007-present, MDACC IRG

Collaborator, An Initiative for Molecular Profiling in Advanced Cancer Therapy (IMPACT) Trial. A Molecular Profile-Based Study in Patients with Advanced Cancer Treated in the Investigational Cancer Therapeutics Program, 2007-0885, PI - Apostolia Tsimberidou, MD, 2009-present

Co-Principal Investigator, A Phase II Study of Biological Response to Dasatinib Treatment in Patients with Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma, 2009-0447, PI - Kevin Kim, 2010, \$385,000, Bristol-Myers Squibb

Co-Principal Investigator, Large Scale Mutational Analysis in Patients at the University of Texas M. D. Anderson Cancer Center, LAB10-0313, PI - Gordon Mills, MD, 2010

Co-Principal Investigator, Phase II Study of IMC-A12 in Patients with Metastatic Uveal Melanoma, 2010-0451, PI - Agop Bedikian, 2011, N01 CM 62202, NCI 8832

Collaborator, Genetic Analysis of Tumor Samples, PA12-0305, PI - Andrew Futreal, MD, 2012

Collaborator, Molecular and clinical correlates of PTEN expression in melanoma, PA12-0875, PI - Michael Davies, MD, 2012-present, NIH

Collaborator, Phase II Study of Nivolumab in combination with Ipilimumab for Uveal Melanoma., 2011-0919, PI - Sapna Patel, MD, 2012, Bristol-Myers Squibb, NIH

Collaborator, Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma, 2013-0147, PI - Sapna Patel, MD, 2013-2015, Prometheus Laboratories

Collaborator, Systemic Therapy of Metastatic Melanoma with Multidrug Regimen Including Interferon, Interleukin-2 and BRAF Inhibitor, 2011-0847, PI - Rodabe Amaria, MD, 2013-2017, MDACC

Collaborator, Molecular Evaluation and/or Biopsy Related Support Program (MEBRS), 2012-0784, PI - David S. Hong, 2013-present, \$135,000

Collaborator, A Phase Ib, Open-Label Study Of The Safety And Pharmacology Of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Vemurafenib Or Vemurafenib Plus Cobimetinib In Patients With BRAF (V-600) Mutation-Positive Metastatic Melanoma, 2012-0588, PI - Patrick Hwu, MD, 2013-present, Genentech

Collaborator, Investigating Immunobiology in Cancer Patients, PA13-0291, PI - Padmanee Sharma, MD, 2013-present, STRATEGIC ALLIANCE: AbbVie Inc

Collaborator, Longitudinal Biopsy Tissue Acquisition Protocol, 2012-0846, PI - Jennifer Wargo, MD, 2013-present, Kennedy Foundation

Collaborator, A Phase I Trial of Ipilimumab (Immunotherapy) and Imatinib Mesylate (c-Kit Inhibitor) in Patients with Advanced Malignancies, 2012-0784, PI - David Hong, MD, 2013

Collaborator, Neoadjuvant and Adjuvant Dabrafenib and Trametinib in Patients with Clinical Stage III Melanoma (Combi-Neo), 2014-0409, PI - Jennifer Wargo, MD, 2014-present, Novartis

Co-Principal Investigator, A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, and Pharmacokinetics of AM0010 in Patients with Advanced Solid Tumors, 2014-0495, PI - Dr. Aung Naing, 2014, ARMO BioSciences

Collaborator, A Multicenter Phase 1, Open-Label, Dose-Escalation Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced Malignancies, 2015-0621, 2015, Deciphera Pharmaceuticals

Collaborator, A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors, 2017-0783, PI - Wen-Jen Hwu, MD, 2015, BMS

Co-Principal Investigator, A Phase II Study of Biological Response to Dasatinib Treatment in Patients with Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma, 2009-0447, PI - Kevin Kim, MD, 2015, BMS

Collaborator, Identification of Tumor-Promoting Viruses in Mucosal and Skin Cancers using Deep Sequencing, LAB10-0609, 2015

Collaborator, Integrated Analysis of Patients with Melanoma, PA15-0308, PI - Isabella Glitza, MD, 2015

Collaborator, Isolation and Use of Human Cells from Human Skin Cancers, LAB08-0750, PI - Ana M. Ciurea, MD, 2015

Collaborator, Phase II Study of Genasense-Carboplatin-Paclitaxel-Combination in Uveal Melanoma, 2010-0188, PI - Sapna Patel, MD, 2015

Collaborator, Phase II study of MK-3475 in conjunction with lymphodepletion, TIL, and high or low dose IL-2 in patients with metastatic melanoma, 2014-0922, PI - Rodabe Amaria, MD, 2015, Merck & Co., Prometheus Laboratories

Collaborator, Neoadjuvant and Adjuvant Checkpoint Blockade in Patients with Clinical Stage III or Oligometastatic Stage IV Melanoma., 2015-0041, PI - Rodabe Amaria, MD, 2016-present, MDACC, Bristol-Myers Squibb

Collaborator, Phenotypic and functional characterization of tumor-infiltrating lymphocytes from human melanoma tissues, LAB06-0755, PI - Chantale Bernatchez, PhD, 2016, NCI

Collaborator, Multi-Center Phase Ib Study of Intermittent Dosing of the MEK inhibitor, Selumetinib, in Patients with advanced Uveal Melanoma Not Previously Treated with a MEK Inhibitor, 2015-0569, PI - Sapna Patel, 2017-present, AstraZeneca

Collaborator, Phase II Study of BEvacizumab in Combination with ATezolizumab in Patients with Untreated Melanoma Brain Metastases (BEAT-MBM), 2016-0866, PI - Hussein Tawbi, MD, 2017-present, MDACC, Genentech

Collaborator, Phase II Study of Oral Azacitidine (CC-486) in Combination with Pembrolizumab (MK-3475) in Patients with Metastatic Melanoma, 2016-0069, PI - Hussein Tawbi, MD, 2017-present, Celgene, MDACC, Merck Pharmaceuticals

Collaborator, Phase I/II Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral CD40 Agonistic Monoclonal Antibody APX005M in Combination with Systemic Pembrolizumab in Patients with Metastatic Melanoma, 2017-0134, PI - Hussein Tawbi, MD, 2017, Bristol-Myers Squibb

#### **Unfunded**

N/A

#### **Patents and Technology Licenses**

##### **Patents**

N/A

##### **Technology Licenses**

N/A

#### **Grant Reviewer/Service on Study Sections**

PRESTIGE Marie Curie post-doc fellowships programme, Research Executive Agency of European Commission, Reviewer, 2016

Melanoma Research Foundation, Scientific Advisory Committee, Reviewer, 2017-present

Biomedicine & F.I.R.S.T. Program, Israel Science Foundation, Reviewer, 2018-present

#### **PUBLICATIONS**

##### **Peer-Reviewed Original Research Articles**

1. **Woodman SE**, Benveniste EN, Nath A, Berman JW. Human immunodeficiency virus type 1 TAT protein induces adhesion molecule expression in astrocytes. *J Neurovirol* 5(6):678-84, 12/1999. PMID: 10602408.
2. McManus CM, Weidenheim K, **Woodman SE**, Nunez J, Hesselgesser J, Nath A, Berman JW. Chemokine and chemokine-receptor expression in human glial elements: induction by the HIV protein, Tat, and chemokine autoregulation. *Am J Pathol* 156(4):1441-53, 4/2000. PMID: PMC1876886.
3. Wu DT, **Woodman SE**, Weiss JM, McManus CM, D'Aversa TG, Hesselgesser J, Major EO, Nath A, Berman JW. Mechanisms of leukocyte trafficking into the CNS. *J Neurovirol* 6 Suppl 1:S82-5, 5/2000. PMID: 10871769.
4. Lee H, **Woodman SE**, Engelman JA, Volonté D, Galbiati F, Kaufman HL, Lublin DM, Lisanti MP. Palmitoylation of caveolin-1 at a single site (Cys-156) controls its coupling to the c-Src tyrosine kinase: targeting of dually acylated molecules (GPI-linked, transmembrane, or cytoplasmic) to caveolae effectively uncouples c-Src and caveolin-1 (TYR-14). *J Biol Chem* 276(37):35150-8, 9/2001. e-Pub 7/2001. PMID: 11451957.
5. **Woodman SE**, Schlegel A, Cohen AW, Lisanti MP. Mutational analysis identifies a short atypical membrane attachment sequence (KYWFYR) within caveolin-1. *Biochemistry* 41(11):3790-5, 3/2002. PMID: 11888297.
6. Park DS, **Woodman SE**, Schubert W, Cohen AW, Frank PG, Chandra M, Shirani J, Razani B, Tang B, Jelicks LA, Factor SM, Weiss LM, Tanowitz HB, Lisanti MP. Caveolin-1/3 double-knockout mice are viable, but lack both muscle and non-muscle caveolae, and develop a severe cardiomyopathic phenotype. *Am J Pathol* 160(6):2207-17, 6/2002. PMID: PMC1850810.



7. Razani B, **Woodman SE**, Lisanti MP. Caveolae: from cell biology to animal physiology. *Pharmacol Rev* 54(3):431-67, 9/2002. PMID: 12223531.
8. **Woodman SE**, Park DS, Cohen AW, Cheung MW, Chandra M, Shirani J, Tang B, Jelicks LA, Kitsis RN, Christ GJ, Factor SM, Tanowitz HB, Lisanti MP. Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. *J Biol Chem* 277(41):38988-97, 10/2002. e-Pub 7/2002. PMID: 12138167.
9. Schubert W, Frank PG, **Woodman SE**, Hyogo H, Cohen DE, Chow CW, Lisanti MP. Microvascular hyperpermeability in caveolin-1 (-/-) knock-out mice. Treatment with a specific nitric-oxide synthase inhibitor, L-NAME, restores normal microvascular permeability in Cav-1 null mice. *J Biol Chem* 277(42):40091-8, 10/2002. e-Pub 8/2002. PMID: 12167625.
10. Cohen AW, Park DS, **Woodman SE**, Williams TM, Chandra M, Shirani J, Pereira de Souza A, Kitsis RN, Russell RG, Weiss LM, Tang B, Jelicks LA, Factor SM, Shtutin V, Tanowitz HB, Lisanti MP. Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42/44 MAP kinase in cardiac fibroblasts. *Am J Physiol Cell Physiol* 284(2):C457-74, 2/2003. e-Pub 10/2002. PMID: 12388077.
11. **Woodman SE**, Ashton AW, Schubert W, Lee H, Williams TM, Medina FA, Wyckoff JB, Combs TP, Lisanti MP. Caveolin-1 knockout mice show an impaired angiogenic response to exogenous stimuli. *Am J Pathol* 162(6):2059-68, 6/2003. PMCID: PMC1868145.
12. Frank PG, **Woodman SE**, Park DS, Lisanti MP. Caveolin, caveolae, and endothelial cell function. *Arterioscler Thromb Vasc Biol* 23(7):1161-8, 7/2003. e-Pub 4/2003. PMID: 12689915.
13. Bonuccelli G, Sotgia F, Schubert W, Park DS, Frank PG, **Woodman SE**, Insabato L, Cammer M, Minetti C, Lisanti MP. Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. *Am J Pathol* 163(4):1663-75, 10/2003. PMCID: PMC1868305.
14. Sotgia F, **Woodman SE**, Bonuccelli G, Capozza F, Minetti C, Scherer PE, Lisanti MP. Phenotypic behavior of caveolin-3 R26Q, a mutant associated with hyperCKemia, distal myopathy, and rippling muscle disease. *Am J Physiol Cell Physiol* 285(5):C1150-60, 11/2003. e-Pub 7/2003. PMID: 12839838.
15. Sotgia F, Bonuccelli G, Minetti C, **Woodman SE**, Capozza F, Kemp RG, Scherer PE, Lisanti MP. Phosphofructokinase muscle-specific isoform requires caveolin-3 expression for plasma membrane recruitment and caveolar targeting: implications for the pathogenesis of caveolin-related muscle diseases. *Am J Pathol* 163(6):2619-34, 12/2003. PMCID: PMC1892361.
16. **Woodman SE**, Sotgia F, Galbiati F, Minetti C, Lisanti MP. Caveolinopathies: mutations in caveolin-3 cause four distinct autosomal dominant muscle diseases. *Neurology* 62(4):538-43, 2/2004. PMID: 14981167.
17. **Woodman SE**, Cheung MW, Tarr M, North AC, Schubert W, Lagaud G, Marks CB, Russell RG, Hassan GS, Factor SM, Christ GJ, Lisanti MP. Urogenital alterations in aged male caveolin-1 knockout mice. *J Urol* 171(2 Pt 1):950-7, 2/2004. PMID: 14713860.
18. De Souza AP, Cohen AW, Park DS, **Woodman SE**, Tang B, Gutstein DE, Factor SM, Tanowitz HB, Lisanti MP, Jelicks LA. MR imaging of caveolin gene-specific alterations in right ventricular wall thickness. *Magn Reson Imaging* 23(1):61-8, 1/2005. PMID: 15733789.
19. Quintás-Cardama A, Lazar AJ, **Woodman SE**, Kim K, Ross M, Hwu P, Medscape. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. *Nat Clin Pract Oncol* 5(12):737-40, 12/2008. e-Pub 10/2008. PMID: 18936790.
20. **Woodman SE**, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Gopal YN, Yang D, Podoloff DA, Ivan D, Kim KB, Papadopoulos N, Hwu P, Mills GB, Davies MA. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. *Mol Cancer Ther* 8(8):2079-85, 8/2009. e-Pub 8/2009. PMID: 19671763.
21. Torres-Cabala CA, Wang WL, Trent J, Yang D, Chen S, Galbincea J, Kim KB, **Woodman S**, Davies M, Plaza JA, Nash JW, Prieto VG, Lazar AJ, Ivan D. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. *Mod Pathol* 22(11):1446-56, 11/2009. e-Pub 8/2009. PMID: 19718013.

22. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, **Woodman SE**, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JE. Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. *Clin Cancer Res* 15(24):7538-7546, 12/2009. e-Pub . PMID: PMC2805170.
23. Gopal YN, Deng W, **Woodman SE**, Komurov K, Ram P, Smith PD, Davies MA. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. *Cancer Res* 70(21):8736-47, 11/2010. e-Pub 10/2010. PMID: 20959481.
24. **Woodman SE**, Williams MD, Esmaeli B. Uveal Melanoma—Molecular Basis and Potential Treatment Targets. *US Ophthalmic Review*, 2011;4(2):131-5
25. Deng W, Vashisht Gopal YN, Scott A, Chen G, **Woodman SE**, Davies MA. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. *PIGM CELL MELANOMA R*. e-Pub 12/2011. PMID: 22171948.
26. Griewank KG, Yu X, Khalili J, Sozen MM, Stempke-Hale K, Bernatchez C, Wardell S, Bastian BC, **Woodman SE**. Genetic and Molecular Characterization of Uveal Melanoma Cell Lines. *PIGM CELL MELANOMA R* 25(2):182-7, 3/2012. e-Pub 2/2012. PMID: PMC3288394.
27. Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizée G, Esmaeli B, **Woodman SE**. Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner. *Clin Cancer Res*. e-Pub 7/2012. PMID: 22733540.
28. Yang Y, Liu C, Peng W, Lizée G, Overwijk WW, Liu Y, **Woodman SE**, Hwu P. Anti-tumor T cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. *Blood*. e-Pub 8/2012. PMID: 22936666.
29. Kim J, Lazar AJ, Davies MA, Homsy J, Papadopoulos NE, Hwu WJ, Bedikian AY, **Woodman SE**, Patel SP, Hwu P, Kim KB. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma. *J Cutan Pathol* 39(9):821-5, 9/2012. e-Pub 7/2012. PMID: 22809251.
30. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Frederick DT, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, **Woodman SE**, Davies MA, Radvanyi LG, Overwijk WW, Lizée G, Hwu P. BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice. *Clin Cancer Res* 19(2):393-403, 1/2013. e-Pub 11/2012. PMID: 23204132.
31. Griewank K, Westekemper H, Murali R, Mach M, Schilling B, Wiesner T, Schimming T, Livingstone E, Sucker A, Grabellus F, Metz C, Susskind D, Hillen U, Speicher MR, **Woodman SE**, Steuhl KP, Schadendorf D. Conjunctival Melanomas harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas. *Clin Cancer Res*. e-Pub 4/2013. PMID: 23633454.
32. Alrwas A, Papadopoulos NE, Cain S, Patel SP, Kim KB, Deburr TL, Bassett R, Hwu WJ, Bedikian AY, Davies MA, **Woodman SE**, Hwu P. Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon- $\alpha$  in patients with metastatic melanoma. *Melanoma Res* 24(4):342-8, 8/2014. PMID: 24743052.
33. Roszik J, **Woodman SE**. HotSpotter: efficient visualization of driver mutations. *BMC Genomics* 15(1):1044. e-Pub 12/2014. PMID: 25435088.
34. Chattopadhyay C, Grimm EA, **Woodman SE**. Simultaneous inhibition of the HGF/MET and Erk1/2 pathways affect uveal melanoma cell growth and migration. *PLoS One* 9(2):e83957, 2014. e-Pub 2/2014. PMID: PMC3923717.
35. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, **Woodman SE**, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA. Beyond BRAF(V600): Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. *J Invest Dermatol* 135(2):508-15, 2/2015. e-Pub 8/2014. PMID: PMC4289407.
36. Genomic Classification of Cutaneous Melanoma. *Cancer Genome Atlas Network*. *Cell*. 2015 Jun 18;161(7):1681-96

37. Tetzlaff MT, Pattanaprichakul P, Wargo J, Fox PS, Patel KP, Estrella JS, Broaddus RR, Williams MD, Davies MA, Routbort MJ, Lazar AJ, **Woodman SE**, Hwu WJ, Gershenwald JE, Prieto VG, Torres-Cabala CA, Curry JL. Utility of BRAF V600E immunohistochemical expression pattern as a surrogate of BRAF mutation status in 154 patients with advanced melanoma. *Hum Pathol.* e-Pub 5/2015. PMID: 26058727.
38. Capparelli C, Rosenbaum S, Berman-Booty LD, Salhi A, Gaborit N, Zhan T, Chervoneva I, Roszik J, **Woodman SE**, Davies MA, Setiady YY, Osman I, Yarden Y, Aplin AE. ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. *Cancer Res.* e-Pub 7/2015. PMID: 26206558.
39. Glitza IC, Haymaker C, Bernatchez C, Vence LM, Rohlf ML, Richard J, Lacey C, Mansaray R, Fulbright OJ, Ramachandran R, Toth C, Wardell S, **Woodman SE**, Patel S, Hwu WJ, Radvanyi L, Davies MA, Papadopoulos NE, Hwu P. Intrathecal administration of tumor-infiltrating lymphocytes is well tolerated in a patient with leptomeningeal disease from metastatic melanoma: A case report. *Cancer Immunol Res.* e-Pub 7/2015. PMID: 26216417.
40. Wilson MA, Zhao F, Khare S, D'Andrea K, Wubbenhorst B, Roszik J, **Woodman SE**, Rimm DL, Kirkwood JM, Kluger HM, Schuchter LM, Lee SJ, Flaherty KT, Nathanson KL. Copy number changes are associated with response to treatment with carboplatin, paclitaxel, and sorafenib in melanoma. *Clin Cancer Res.* e-Pub 8/2015. PMID: 26307133.
41. Han L, Diao L, Yu S, Xu X, Li J, Zhang R, Yang Y, Werner HM, Eterovic AK, Yuan Y, Li J, Nair N, Minelli R, Tsang YH, Cheung LW, Jeong KJ, Roszik J, Ju Z, **Woodman SE**, Lu Y, Scott KL, Li JB, Mills GB, Liang H. The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. *Cancer Cell* 28(4):515-28, 10/2015. e-Pub 10/2015. PMCID: PMC4605878.
42. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li H, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, **Woodman SE**, Overwijk WW, Lizee G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi LG, Davies MA, Hwu P. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. *Cancer Discov.* e-Pub 12/2015. PMID: 26645196. [**Leader of large-scale characterization of cell lines utilized in this study**].
43. Ekmekcioglu S, Davies MA, Tanese K, Roszik J, Shin-Sim M, Bassett RL, Milton DR, **Woodman SE**, Prieto VG, Gershenwald JE, Morton DL, Hoon DS, Grimm EA. Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and its Expression Associates with Favorable Survival for Stage III Melanoma. *Clin Cancer Res.* e-Pub 1/2016. PMID: 26783288.
44. Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, **Woodman SE**, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. *Oncoimmunology* 5(3):e1136044, 3/2016. e-Pub 2/2016. PMCID: PMC4839346.
45. Chattopadhyay C, Kim DW, Gombos DS, Oba J, Qin Y, Williams MD, Esmaili B, Grimm EA, Wargo JA, **Woodman SE**, Patel SP. Uveal melanoma: From diagnosis to treatment and the science in between. *Cancer.* e-Pub 3/2016. PMID: 26991400.
46. Johnson DB, Roszik J, Shoushtari AN, Eroglu Z, Balko J, Higham C, Puzanov I, Patel SP, Sosman JA, **Woodman SE**. Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum. *Pigment Cell Melanoma Res.* e-Pub 4/2016. PMID: 27089234.
47. Yoo JH, Shi DS, Grossmann AH, Sorensen LK, Tong Z, Mleynek TM, Rogers A, Zhu W, Richards JR, Winter JM, Zhu J, Dunn C, Bajji A, Shenderovich M, Mueller AL, **Woodman SE**, Harbour JW, Thomas KR, Odelberg SJ, Ostanin K, Li DY. ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma. *Cancer Cell* 29(6):889-904, 6/2016. e-Pub 6/2016. PMID: 27265506.

48. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, **Woodman SE**, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. *Cancer Discov* 6(8):827-37, 8/2016. e-Pub 6/2016. PMID: 27301722.
49. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C, **Woodman SE**, Chen PL, Hwu P, Allison JP, Futreal A, Wargo JA, Sharma P. Loss of IFN- $\gamma$  Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. *Cell* 167(2):397-404.e9, 10/2016. e-Pub 9/2016. PMID: PMC5088716. [**Leader of large-scale characterization of cell lines utilized in this study**].
50. Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, **Woodman SE**. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. *BMC Med* 14(1):168, 10/2016. e-Pub 10/2016. PMID: PMC5078889.
51. Kim DW, Haydu LE, Joon AY, Bassett RL, Siroy AE, Tetzlaff MT, Routbort MJ, Amaria RN, Wargo JA, McQuade JL, Kemnade J, Hwu P, **Woodman SE**, Roszik J, Kim KB, Gershenwald JE, Lazar AJ, Davies MA. Clinicopathological features and clinical outcomes associated with TP53 and BRAF(N)(on-)(V)(600) mutations in cutaneous melanoma patients. *Cancer*. e-Pub 12/2016. PMID: 27911979.
52. Roszik J, Wu CJ, Siroy AE, Lazar AJ, Davies MA, **Woodman SE**, Kwong LN. Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. *Sci Rep* 6:19649, 2016. e-Pub 1/2016. PMID: PMC4726397.
53. Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, **Woodman SE**, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. *Sci Transl Med* 9(379), 3/2017. PMID: 28251903.
54. Park J, Talukder AH, Lim SA, Kim K, Pan K, Melendez B, Bradley SD, Jackson KR, Khalili JS, Wang J, Creasy C, Pan BF, **Woodman SE**, Bernatchez C, Hawke D, Hwu P, Lee KM, Roszik J, Lizée G, Yee C. SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity. *Cancer Immunol Res*. e-Pub 6/2017. PMID: 28630054. [**Leader of large-scale characterization of cell lines utilized in this study**].
55. Johnson CP, Kim IK, Esmaeli B, Amin-Mansour A, Treacy DJ, Carter SL, Hodis E, Wagle N, Seepo S, Yu X, Lane AM, Gragoudas ES, Vazquez F, Nickerson E, Cibulskis K, McKenna A, Gabriel SB, Getz G, Van Allen EM, 't Hoen PAC, Garraway LA, **Woodman SE**. Systematic genomic and translational efficiency studies of uveal melanoma. *PLoS One* 12(6):e0178189, 2017. e-Pub 6/2017. PMID: PMC5464544. [**Senior and Co-Corresponding Author**]
56. Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O, Akbani R, Bristow CA, Hoadley KA, Iype L, Chang MT, Cherniack AD, Benz C, Mills GB, Verhaak RGW, Griewank KG, Felau I, Zenklusen JC, Gershenwald JE, Schoenfeld L, Lazar AJ, Abdel-Rahman MH, Roman-Roman S, Stern MH, Cebulla CM, Williams MD, Jager MJ, Coupland SE, Esmaeli B, Kandoth C, **Woodman SE**. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. *Cancer Cell*. 2017; 32(2):204-220.e15. PMID: 28810145 [**Senior and Co-Corresponding Author**]
57. Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K,

- Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, **Woodman SE**, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. *NPJ Genomic Med.* 2017;2. pii: 10. Epub 2017 Apr 7. PMID: 28819565
58. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Sloane RS, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Sanchez EMR, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, **Woodman SE**, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science.* e-Pub 11/2017. PMID: 29097493.
59. Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, **Woodman SE**, Davies MA, Wargo JA. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. *Lancet Oncol* 19(2):181-193, 2018. e-Pub 1/2018. PMID: 29361468. **[The genomic and molecular analyses in this study were generated from the Woodman Laboratory].**
60. Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets TV, Haymaker C, Forget MA, Williams LJ, Wang Z, Mbofung R, Wang ZQ, Davis RE, Lo RS, Wargo JA, Davies MA, Bernatchez C, Heffernan TP, Amaria RN, Korkut A, Peng W, Roszik J, Lizee G, **Woodman SE**, Hwu P. The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression. *Clin Cancer Res.* e-Pub 3/2018. PMID: 29496759 **[Leader of large-scale characterization of cell lines utilized in this study].**
61. Glitza IC, Rohlf M, Guha-Thakurta N, Bassett RL, Bernatchez C, Diab A, **Woodman SE**, Yee C, Amaria RN, Patel SP, Tawbi H, Wong M, Hwu WJ, Hwu P, Heimberger A, McCutcheon IE, Papadopoulos N, Davies MA. Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. *ESMO Open* 3(1):e000283, 2018. e-Pub 1/2018. PMCID: PMC5786950.

#### Invited Articles

1. Patel SP, **Woodman SE**. Profile of ipilimumab and its role in the treatment of metastatic melanoma. *Drug Design, Development and Therapy* 5:489-95, 2011. e-Pub 12/2011. PMID: 22267918.
2. **Woodman SE**, Davies MA. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. *Biochemical Pharmacology* 80(5):568-74, 9/2010. e-Pub 5/2010. PMID: 20457136.
3. **Woodman SE**, Lazar AJ, Aldape KD, Davies MA. New Strategies in Melanoma: Molecular Testing in Advanced Disease. *Clinical Cancer Research.* e-Pub 1/2012. PMID: 22275506.
4. **Woodman SE**. Metastatic uveal melanoma: biology and emerging treatments. *Cancer Journal* 18(2):148-52, Mar-Apr, 3/2012. PMID: 22453016.
5. Jager MJ, Dogrusöz M, **Woodman SE**. Uveal Melanoma: Identifying Immunological and Chemotherapeutic Targets to Treat Metastases. *Asia Pacific Journal of Ophthalmology* 6(2):179-185, Mar-Apr, 3/2017. PMID: 28399339.

#### Editorials

1. **Woodman SE**, Mills GB. Are oncogenes sufficient to cause human cancer? Proceedings of the National Academy of Sciences USA 107(48):20599-600, 11/2010. e-Pub 11/2010. PMID: 2096413.
2. **Woodman SE**. BAP1 loss of a Tumor Suppressor. Clinical Cancer Research 18(2):323-5, 1/2012. e-Pub 12/2011. PMID: 22140212.
3. Peng G, **Woodman SE**, Mills GB. RAD51 response puts an exceptional responder in CHK1: a synthetic lethal curative response to DNA-damaging chemotherapy? Cancer Discovery 4(9):988-90, 9/2014. PMID: 245513.

#### Other Articles

N/A

#### Abstracts

1. Sotgia F, **Woodman SE**, Bonuccelli G, Capozza F, Minetti C, Scherer PE, Lisanti MP. Phenotypic Behavior of Caveolin-3 R26Q, a Mutant Associated with HyperCKemia, Distal Myopathy, and Rippling Muscle Disease. American Journal of Physiology-Cell Physiology. 2003;54(5):C1150.
2. **Woodman SE**, Trent JC, Stemke-Hale K, Lazar A, Priol S, Pavan GM, Papadopoulos N, Hwu P, Mills GB, Davies MA. Selective Activity of Dasatinib for the Most Common KIT Mutation in Melanoma (L576P). Journal of Clinical Oncology 27, no. 15\_suppl (May 2009) 9019. (Presented at ASCO Annual Meeting, Orlando, FL, 2009)
3. SJ Dorkhom, J Kim, AJF Lazar, MA Davies, J Homsy, NE Papadopoulos, W Hwu, AY Bedikian, **Woodman SE**, SP Patel, P Hwu, KB Kim. BRAF, NRAS, and KIT Mutational Analysis of Spindle Cell Melanoma. Journal of Clinical Oncology 29, no. 15\_suppl (May 2011) 8589.
4. Patel SP, Bedikian AY, Papadopoulos NE, Hwu W, Kim KB, Homsy J, Davies MA, **Woodman SE**, Radvanyi LG, Woodard K, Mahoney S, Hwu P. Ipilimumab Plus Temozolomide in Metastatic Melanoma. Journal of Clinical Oncology 29, no. 15\_suppl (May 2011) 8579.
5. **Woodman SE**, Yu X, Chattopadhyay C, Poindexter N, Grimm E. GNAQ/11 Mutant Dependent Uveal Melanoma Sensitivity to MEK and PI3K Inhibitors. National Cancer Institute Translational Science Meeting, 2011
6. Bedikian AY, Kim KB, Papadopoulos NE, Hwu W, Patel SP, Davies MA, Mahoney S, Hwu P, **Woodman SE**. Phase I/II Study of LOC-paclitaxel (LOC-Pac) in Patients (pts) with Metastatic Melanoma. Journal of Clinical Oncology 30, no. 15\_suppl (May 2012) 19039.
7. Chattopadhyay C, Poindexter, **Woodman SE**, Esmaeli B, Grimm EA. Targeting c-Met/HGF Pathway in Uveal Melanoma Cells. Investigative Ophthalmology & Visual Science, 52 (14): 1443. (Presented at ARVO Annual Meeting, April 2011)
8. **Woodman SE**, Yu X, Chattopadhyay C, Williams M, Poindexter N, Jager MJ, Grimm E, Esmaeli B. GNAQ/11 Mutant Dependent Uveal Melanoma Sensitivity to MEK and PI3K Inhibitors., (Presented at the International Society of Ocular Oncology International Meeting, 11/2011)
9. Alrwas A, Papadopoulos NE, Cain S, Patel SP, Kim KB, Deburr TL, Bassett R, Hwu W, Bedikian AY, Davies MA, **Woodman SE**, Hwu P. Phase I study of Nab-paclitaxel (NP) in Combination with Biochemotherapy (BCT) in Patients (pts) with Metastatic Melanoma (MM). Journal of Clinical Oncology 30, no. 15\_suppl (May 2012) 19009.
10. Chattopadhyay C, **Woodman SE**, Esmaeli B, Grimm EA. Targeting IGF-1R In Uveal Melanoma Cells. Investigative Ophthalmology & Visual Science, 2012; 53(14): 3396 (Presented at ARVO Annual Meeting, March 2012)
11. Yang Y, Liu C, Peng W, Mbofung RN, Lizee G, Overwijk WW, **Woodman SE**, Hwu P. The Anti-tumor T Cell Response Plays a Critical Role in the Therapeutic Effect of Dasatinib on C-kit Mutant Mastocytoma and can be Potentiated by Anti-OX40 Antibody. Journal of Immunotherapy. 35(9): 775. 2012.
12. Nowroozi S, Zuo Z, Patel K, Patel SP, Luthra R, Routbort M, Alexander JF, Lazar, Davies MA, Hasanein H, Papadopoulos NE, Hwu WJ, Bedikian AY, **Woodman SE**, Hwu P, Kim KB. Clinical Characteristics of Melanoma Patients with non-V600E/K BRAF Mutations. Journal of Clinical Oncology 31, no. 15\_suppl (May 2013) e20036.

13. Chattopadhyay C, Grimm E, **Woodman SE**. Simultaneous Inhibition of the HGF/MET and Erk1/2 Pathways Affect Uveal Melanoma Cell Growth Migration. *Investigative Ophthalmology & Visual Science, Proceedings of ARVO 2013* 54(15):4211, 6/2013.
14. Griewank KG, Westekemper H, Schilling B, Mach M, Murali R, Wiesner T, Schimming T, Grabellus F, Metz C, Sucker A, Hillen U, Speicher M, **Woodman SE**, Steuhl K, Schadendorf D. Oncogene and Copy Number Analysis of a Larger Cohort of Conjunctival Melanoma. *Experimental Dermatology*. 22(3): e43. 2013
15. Alrwas A, Alvarado G, Bernatchez C, Wei C, Radvanyi L, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Papadopoulos NE, Kim KB, Bedikian AY, Hwu WJ, Patel SP, **Woodman SE**, Davies ME, Ross MI, Lee J, Gershenwald J, Cormier J, Lucci A, Royal R, Hwu P. Tumor-infiltrating Lymphocyte (til) Growth as a Prognostic Factor in Patients (pts) with Metastatic Melanoma (mm). *Pigment Cell & Melanoma Research*. 26 (6): 934. 2013
16. Siroy AE, Prieto VG, Gershenwald JE, **Woodman SE**, Roszik J, Aldape KD, Luthra R, Patel KP, Routbort MJ, Davies MA, Lazar AJ. Clinical Next-Generation Sequencing Reveals Divergent Mutational Patterns in BRAF V600, BRAF Non-V600, and NRAS Mutations in Advanced Melanoma. In *Laboratory Investigation*. 2014 Feb 1 (Vol. 94, pp. 143A).
17. Joon L, Haydu V, Baladandayuthapani, Stingo F, **Woodman SE**, Amaria RN, Wargo JA, Shaw KR, Meric-Bernstam F, Mills GB, Gershenwald JE, Hwu P, Lazar A, Davies ME. Next Generation Sequencing of 201 Cancer Related genes in Melanoma. *Pigment Cell & Melanoma Research*. 27(6):1184, NOV 2014.
18. Glitza IC, Bernatchez C, Bassett RL, Vaughn C, Velasquez P, Diab A, Amaria RN, Yee C, **Woodman SE**, Pate SP, Kim KB, Davies MA, Papadopoulos NE, Bedikian AY, Hwu WJ, Radvanyi LG, Hwu P. Treatment with Tumor-Infiltrating Lymphocytes (TIL) in Metastatic Melanoma and Clinical Benefit Regardless of Site of Origin, Mutation Status, or Prior Checkpoint Blockade. *Journal of Clinical Oncology* 32, no. 15\_suppl (May 2014) 9079.
19. Wong F, Chen SY, **Woodman SE**, Kim KB. Early Metabolic Responses on FDG PET-CT in 7 Days Correlate with Progression-free Survival (PFS) in Patients with Metastatic Melanomas after Initiation of Targeted Therapy. *J Nucl Med* May 2014 vol. 55 no. supplement 1 653.
20. Kim DW, Nowroozi S, Kim K, Davies MA, Routbort M, Lazar AJF, Frankian S, Siroy A, Bedikian AY, Papadopoulos NE, Hwu WJ, Hwu P, **Woodman SE**, Patel SP, Kim KB. Clinical Characteristics of Patients with non-V600 BRAF Mutant Melanomas. *Journal of Clinical Oncology* 32, no. 15\_suppl (May 2014) 9100.
21. Kim D, Kim K, Papadopoulos N, Bedikian AB, Hwu WJ, Frankian S, Siroy A, Routbort M, Haydu L, Lazar A, Diab A., Amaria RN, **Woodman SE**, Patel SP, Hwu P, Davies M. Pathological and Clinical Characteristics of TP53 Mutations in Patients with Melanoma. *Pigment Cell & Melanoma Research*. 27(6):1202–1203, Nov 2014
22. Roszik J, Joon A, Siroy A, Haydu L, Stingo F, Baladandayuthapani V, Hwu P, Tetzlaff M, Wargo J, Chen JQ, Radvanyi L, Bernatchez C, Gershenwald J, Lazar AJ, Davies MA, **Woodman SE**. A Novel Algorithm Applicable to Cancer Next Generation Sequencing Panels Accurately Predicts Total Tumor Mutation Load and Correlates with Clinical Outcomes in Melanoma. *Journal of Clinical Oncology* 33, no. 15\_suppl (May 2015) 9071. (Presented at ASCO Annual Meeting 2015).
23. Kim DW, Haymaker C, McQuail N, Sirmans E, Spencer C, Glitza I, Amaria R, **Woodman SE**, Patel SP, Davies ME, Yee C, Hwu WJ, Bernatchez C, Wargo J, Sharma P, Allison J, Hwu P, Tam A, Diab A. Pilot Study of Intratumoral (IT) Cryoablation (cryo) in Combination with Systemic Checkpoint Blockade in Patients with Metastatic Melanoma (MM). *Journal for ImmunoTherapy of Cancer* 2015; 3(Suppl 2):P137
24. Tetzlaff M, Pattanaprichakul P, Wargo J, Fox P, Patel K, Estrella J, Broaddus R, Davies ME, Routbort M, Lazar A, Prieto V, Hwu WJ, Gershenwald J, **Woodman SE**, Torres-Cabala C, Curry J. Utility of BRAFV600E Immunohistochemistry (IHC) Expression Pattern as a Surrogate of BRAFV600 Mutation Status in 154 Patients with Advanced Stage Melanoma. In *Laboratory Investigation* 2015 Feb 1 (Vol. 95, pp. 126A).
25. Kim IK, Place CS, Esmaeli B, Amin-Mansour, Lane AM, Gragoudas ES, Van Allen EM, Garraway LA, **Woodman SE**. Exome Sequencing of Primary and Metastatic Uveal Melanoma, *Retinal Society Annual Meeting*, 2015

26. Oba J, Wang WL, Eterovic AK, Stephan CC, Roszik J, Charuta R. Kale, Haymaker CL, Routbort M, Haydu LE, Bernatchez CE, Davies MA, Lazar AJF, Grimm EA, **Woodman SE**. Global Genomic and Small Molecule Inhibitor Interrogation of KIT Mutant Melanoma Reveals Underlying Biology and Implicates Novel Molecular Targets. *Journal of Clinical Oncology* 33, no. 15\_suppl (May 2015) 9039. (Presented at ASCO Annual Meeting 2015)
27. Davies MA, Joon A, Bassett RL, Roszik J, Siroy A, Haydu LE, Chen K, Stingo F, Baladandayuthapani V, Shaw KR, Bernstam FM, Tetzlaff MT, Gershenwald JE, **Woodman SE**, Lazar AJF. Demographics, Tumor Characteristics, and Clinical Outcomes Associated with Somatic Mutations in 201 Cancer-related Genes in Advanced Melanoma Patients (pts). *Journal of Clinical Oncology* 33, no. 15\_suppl (May 2015) 9057. (Presented at ASCO Annual Meeting 2015)
28. Glitza IC, Rohlf ML, Bassett R, John I, Richard J, Iqbal M, Bernzen T, Gerber DL, Lacey C, Diab A, Amaria RM, **Woodman SE**, Patel SP, Yee CC, Hwu WJ, Hwu P, Papadopoulos N, Davies MA. Abstract 517: Long-term Efficacy of Intrathecal Interleukin-2 (IT IL2) in Metastatic Melanoma (MM) Patients (pts) with Leptomeningeal Disease (LMD). *Journal: European Journal of Cancer* 09/2015 (51): S109 (Presented at European Cancer Congress 2015)
29. Roth KG, Siroy AE, Tetzlaff M, Roszik J, Meric-Bernstam F, Shaw KR, Mills GB, Routbort M, Hess KR, Haydu LE, Gershenwald J, Lazar A, Davies M, **Woodman SE**. Mutation and Clinical Analysis of a Large Cohort of Acral and Mucosal Melanomas, 2015.
30. Johnson CP, Kim IK, Esmaeli B, Amin-Mansour, Treacy DJ, Carter SL, Hodis E, Wagle N, Seepo S, Yu X, Vasquez F, Nickerson E, Cibulskis K, McKenna A, Gabriel SB, Getz G, Van Allen EM, Garraway LA, **Woodman SE**. Systematic Genomic Characterization of Uveal Melanoma. *Cancer Research* 2015 Nov 75(22) Supp1: A1-15 (Presented at AACR Special Conference: Translation of the Cancer Genome; 02/2015)
31. Reuben A, Spencer C, Jason R, Miller J, Kwong L, Jiang H, Haymaker C, Chen PL, Austin-Breneman J, Roh W, Little L, Cao Y, Garber H, Forget MA, Gopalakrishnan V, Amaria R, Davies ME, Bernatchez C, Roger E, Cuentas P, Rodriguez J, Tetzlaff M, **Woodman SE**, Dwyer K, Sharma P, Allison J, Chin L, Futreal A, Cooper Z and Jennifer Wargo. Molecular and Immune Heterogeneity in Synchronous Melanoma Metastases. *Journal for ImmunoTherapy of Cancer* 20153(Suppl 2):P262. (Presented at Society for Immunotherapy of Cancer 11/ 2015).
32. De Macedo MP, Reuben A, Qin Y, Reddy S, Spencer CN, Jiang H, Bernatchez C, Austin-breneman JL, Gopalakrishnan V, Guindani M, Gombos D, Esmaeli B, Grimm EA, Chattopadhyay C, Oba J, **Woodman SE**, Hwu P, Williams M, Tetzlaff M, Cooper ZA, Wargo JA, Lazar A, Patel S. Understanding the Determinants of Resistance to Therapy in Metastatic Uveal Melanoma. *Pigment Cell & Melanoma Research*. 28(6):806, 11/2015 (Presented at Society for Melanoma Research Congress, 2015)
33. Amaria RN, Bassett RL, Simpson L, Delaney F, Hwu P, Kim KB, Hwu WJ, Patel SP, Glitza IC, Davies MA, **Woodman SE**, Yee C, Bedikian AY. Abstract e20014: Phase I Study of Ipilimumab (IPI) with Biochemotherapy (BCT) for Chemo-naïve Patients with Metastatic Melanoma (MM). *Journal of Clinical Oncology* 33, no. 15\_suppl e20014.
34. Kemnade J, Roszik J, Joon A, Stingo F, Baladandayuthapani V, Lazar AJF, **Woodman SE**, Davies MA. Abstract 9064: Identification of Potentially Actionable Mutations in RTKs in Melanoma Detected by Next Generation Sequencing (NGS). *Journal of Clinical Oncology* 33, no. 15\_suppl (May 2015) 9064.
35. Chen PL, Roh W, Reuben A, Spencer CN, Jiang H, Lazar A, Davies MA, Miller JP, Wani K, Hwu P, Patel SP, **Woodman SE**, Glitza IC, HWJ, Cooper ZA, Allison J, Sharma, P. Wistuba I, Blando J, Prieto V, Tetzlaff M, Amaria RN, Futreal A, Chin L, Wargo JA. Immune Infiltrate in Early On-Treatment Biopsies is Highly Predictive of Response to Immune Checkpoint Blockade. *Pigment Cell & Melanoma Research*. 28(6):763, Nov 2015.
36. Kim DW, Haymaker C, Perdon K, Amaria R, Mcquail N, Fa'ak F, Spencer CB, Sirmans E, Glitza I, Wargo JA, **Woodman SE**, Patel S, Davies ME, Hwu WJ, Bernatchez C, Hwu P, Diab A. Phase II Trial of Nab-Paclitaxel (ABI) Plus Ipilimumab (ipi) in Patients with Metastatic Melanoma (MM). *Pigment Cell & Melanoma Research*. 28(6):785–786, NOV 2015. (Presented at the Society for Melanoma Research, 2015)



37. Glitza IC, Rohlf M, Bassett R, John I, Richard J, Iqbal M, Bernzen T, Gerber D, Lacey C, Diab A, Amaria R, **Woodman SE**, Patel SP, Yee C, Hwu WJ, McCutcheon IE, Heimberger A, Hwu P, Papadopoulos NE, Davies MA. IMCT-07 Therapeutic Outcomes of Intrathecal Interleukin-2 in Metastatic Melanoma Patients with Leptomeningeal Disease (LMD). *Neuro-Oncology*, Volume 17, Issue suppl\_5, 1 November 2015, Pages v108. (Presented at the Society for Neuro-Oncology Meeting, 11/2015)
38. Austin-Breneman JL, Reuben A, Spencer CN, Roszik J, Miller JP, Kwong L, Jiang H, Roh W, Cao Y, Little LD, Amaria RN, Garber HR, Gopalakrishnan V, Chen PL, Haymaker C, Forget MA, Davies M, Bernatchez C, Tetzlaff M, **Woodman SE**, Dwyer KC, Chin L, Futreal A, Cooper ZA, Wargo JA. Immune and Molecular Heterogeneity in Synchronous Melanoma Metastases. *Pigment Cell & Melanoma Research*. 28(6):755, NOV 2015.
39. Karpinets T, Calderone T, Wani K, Yu X, Creasy C, Haymaker C, Forget M, Nanda V, Roszik J, Wargo J, Haydu L, Song X, Lazar A, Gershenwald J, Davies M, Bernatchez C, Zhang J, Futreal A, **Woodman SE**. Melanoma Reprogramming State Correlates with Response to CTLA-4 Blockade in Metastatic Melanoma. *Hum Genomics*. 2016; 10(Suppl 1): 12. PMID: PMC4896275. (Presented at Human Genome Meeting 2016, February 28 – March 2, 2016; Houston, TX, USA)
40. Kim DW, Haydu LE, Joon A, Basset RL, Siroy A, Tetzlaff MT, Lazar A, **Woodman SE**, Gershenwald JE, Davies MA. Pathological and Clinical Features of Non-acral Cutaneous Melanoma Patients with TP53 and BRAFNon-V600 mutations. *Journal of Clinical Oncology* 34, no. 15\_suppl (May 2016) 9535-9535. (Presented at ASCO)
41. Amaria RN, Haymake CL, Bernatchez C, Forget ME, Pate V, Hwu WJ, Davies ME, Patel SP, Diab A, Glitza IC, Tawbi HA, **Woodman SE**, Wargo JE, Ross MI, Lee JE, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Hwu P. A Phase I/II Study of Lymphodepletion Plus Adoptive Cell Transfer (ACT) with T Cells Transduced with CXCR2 and NGFR Followed by High Dose Interleukin-2 (IL-2) in Patients with Metastatic Melanoma (MM). *Journal of Clinical Oncology* 34, no. 15\_suppl 9594. 2016.
42. Lundqvist A, Hoef VV, Zhang X, Wennerberg E, **Woodman SE**, Hwu WJ, Davies MA, Hwu P, Valsesia-Wittmann S, Shekarian T, Simard F, Nailo R, Dutour A, Jallas AC, Caux C, Marabelle A. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. National Harbor, MD, USA. 9-13 November 2016.
43. Yang H, Li Z, Zhang Q, Craven CM, **Woodman SE**, McCannel TA, Grossniklaus HE. Loss of BAP1 Results in High Metastatic Rate in a Mouse Ocular Melanoma Model. 2016 *Investigative Ophthalmology & Visual Science* 57 (12), 4105 (presented at ARVO Annual Meeting 2016)
44. Reuben A, Spencer CN, Prieto PA, Miller JP, Mao X, Chen WS, Cheung H, Jiang H, Haymaker C, Petaccia M, Garber HR, Chen PL, Gopalakrishnan V, Austin-Breneman J, Hudgens CW, Roszik J, Hwu P, **Woodman SE**, Chin L, Davies MA, Amaria RN, Patel SP, Lazar AJ, Tetzlaff MT, Dwyer KC, Wistuba II, Sharma P, Allison JP, Zhang J, Futreal A, Cooper ZA and Wargo JA. Abstract 2392: Genomic and Immune Heterogeneity in Synchronous Melanoma Metastases is Associated with Differential Tumor Growth and Response to Therapy. *Cancer Res* July 15 2016 (76) (14 Supplement) 2392. (Presented at AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA)
45. Chattopadhyay C, **Woodman SE**. Monosomy 3 Uveal Melanoma Cells Have a Unique Metabolic Phenotype Distinct from Disomy 3, June 2017. *Investigative Ophthalmology & Visual Science* 58 (8), 2504 (Presented at ARVO Annual Meeting 2017)
46. Haymaker C, Uemura M, Murthy R, James M, Wang D, Brevard J, Swann S, Geib J, Cornfeld M, Chunduru S, Agrawal S, Yee C, Wargo J, Amaria R, Patel S, Tawbi H, Glitza I, **Woodman SE**, Hwu WJ, Davies MA, Hwu P, Overwijk W, Bernatchez C, Diab A. Translational Evidence of Reactivated Innate and Adaptive Immunity with Intratumoral IMO-2125 in Combination with Systemic Checkpoint Inhibitors from a Phase I/II Study in Patients with Anti-PD-1 Refractory Metastatic Melanoma. (Presented at AACR Annual Meeting 2017).
47. Yang H, Tan S, Grossniklaus HE, Morales VM, Zhang Q, Burgess BL, Hu DN, **Woodman SE**, McCannel TA, Yang J. CXCR4 Expression in an Intraocular Melanoma Mouse Model

- with Hepatic Metastases, June 2017. *Investigative Ophthalmology & Visual Science* 58 (8), 1254 (presented at ARVO Annual Meeting 2017)
48. Wargo JA, Amaria RN, Prieto PA, Andrews MC, Tetzlaff MT, Futrea PA, Hwu P, Hwu WJ, Glitza IC, Tawbi HA, Cormier JN, Lee JE, Patel SP, Simpson LE, Burton EM, Bassett RL, Ross MI, Gershenwald JE, Davies MA, **Woodman SE**. Relapse-free Survival and Target Identification to Enhance Response with Neoadjuvant and Adjuvant Dabrafenib + Trametinib (D+T) Treatment Compared to Standard-of-Care (SOC) Surgery in Patients (pts) with High-Risk Resectable BRAF-Mutant Metastatic Melanoma. *Journal of Clinical Oncology* 35, no. 15\_suppl (May 2017) 9587. (Presented at ASCO Annual Meeting 2017)
  49. Dumbrava EE, Brusco L, Daniels MS, Wathoo C, Shaw KR, Lu KH, Zheng X, Strong LC, Litton JK, Arun B, Eterovic AK, Piha-Paul SA, Subbiah V, Hong DS, **Woodman SE**, Mendelsohn J, Yap TA, Mills GB, Chen K, Meric-Bernstam F. Pathogenic Variants in DNA Damage Response (DDR) Genes in Patients with Advanced Solid Tumors. *Journal of Clinical Oncology* 35, no. 15\_suppl (May 2017) 11567. (Presented at ASCO Annual Meeting 2017)
  50. Chen WS, Andrews MC, Spencer C, Tawbi HA, Lazar A, Tetzlaff MT, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Amaria RN, Burton EM, **Woodman SE**, Davies MA, Gershenwald JE, Sharma P, Allison JP, Futreal A, Wargo JA. Molecular and Immune Predictors of Response and Toxicity to Combined CTLA-4 and PD-1 Blockade in Metastatic Melanoma (MM) Patients (pts). *Journal of Clinical Oncology* 35, no. 15\_suppl (May 2017) 9579. (Presented at ASCO Annual Meeting 2017)
  51. Royal RE, Vence LM, Wray T, Cormier JN, Lee JE, Gershenwald JE, Ross MI, Wargo JA, Amaria RN, Davies MA, Diab A, Glitza IC, Hwu WJ, Patel SP, **Woodman SE**, Overwijk WW, Hwu P. A Toll-like Receptor Agonist to Drive Melanoma Regression as a Vaccination Adjuvant or by Direct Tumor Application. *Journal of Clinical Oncology* 35, no. 15\_suppl 9582. (Presented at ASCO Annual Meeting 2017)
  52. Keung E, Burton EM, Amaria RN, Glitza IC, Patel SP, Diab A, Yee C, Wong MK, Hwu WJ, Hwu P, **Woodman SE**, Tetzlaff MT, Milton D, Perez K, Davies MA, Rai K, Wargo JA, Tawbi HA. A Phase II Study of Oral Azacitidine (CC-486) in Combination with Pembrolizumab (PEMBRO) in Patients with Metastatic Melanoma (MM). *Journal of Clinical Oncology* 35, no. 15\_suppl 9594. (Presented at ASCO Annual Meeting 2017)
  53. Reddy SM, Rodabe N, Amaria, Christine N. Spencer, Michael Tetzlaff, Alexandre Reuben, Miles Andrews, Linghua Wang, **Woodman SE**, Haifeng Zhu, Jorge Blando, Luis Vence, Shaojun Zhang, Hong Jiang, Vancheswaran Gopalakrishnan, Courtney Hudgens, Khalida Wani, Hussein Tawbi, Adi Diab, Isabella Glitza, Sapna Patel, Wen-Jen Hwu, Michael Wong, Patrick Hwu, Janice Cormier, Anthony Lucci, Richard Royal, Jeffrey E. Lee, Lauren Simpson, Elizabeth M. Burton, Jeffrey E. Gershenwald, Merrick Ross, James Allison, Padmanee Sharma, Michael Davies, Wargo J. Neoadjuvant nivolumab versus combination ipilimumab and nivolumab followed by adjuvant nivolumab in patients with resectable stage III and oligometastatic stage IV melanoma: preliminary findings. (#O15), SITC 2017. *Journal for ImmunoTherapy of Cancer* 2017 5(Suppl 2):86
  54. Cascone T, Jodi Alicia McKenzie, Rina Mbofung, Simone Punt, Zhe Wang, Chunyu Xu, Leila Williams, Zhiqiang Wang, Christopher Bristow, Alessandro Carugo, Michael Peoples, Lerong Li, Tatiana Karpinets, Shruti Malu, Caitlin Creasy, Sara Leahey, Jiong Chen, Chantale Bernatchez, Y. N. Vashisht Gopal, Timothy P. Heffernan, Jianhua Hu, Jing Wang, Rodabe N. Amaria, Levi A. Garraway2, Ignacio I. Wistuba, **Woodman SE**, Jason Roszik, R. Eric Davis, Michael A. Davies, John V. Heymach, Patrick Hwu, Peng W. Functional correlation of increased tumor intrinsic glycolytic activity with resistance to adoptive T cell therapy. SITC 2017. *Journal for ImmunoTherapy of Cancer* 2017 5(Suppl 2):86
  55. Johnson DH, Zobniw C, Trinh VA, Bassett R, Ma J, Anderson J, Davis J, Jocelyn Joseph, Marc Uemura, Cassian Yee, Rodabe Amaria, Sapna Patel, Hussein Tawbi, Isabella Glitza, Michael A Davies, Michael Wong, **Woodman SE**, Patrick Hwu, Wen-Jen Hwu, Yinghong Wang, Diab A. Infliximab associated with faster symptom resolution compared to corticosteroids alone for management of immune related enterocolitis SITC 2017. *Journal for ImmunoTherapy of Cancer* 2017 5(Suppl 2):86
  56. Andrews M, Chen WS, Spencer C, Gopalakrishnan V, Tawbi H, Lazar A, Tetzlaff M, Patel S, Hwu P, Hwu WJ, Diab A, Glitza I, AMaria R, Burton E, **Woodman SE**, Davies M,

- Gershenwald J, Sharma P, Allison J, Futreal A, Wargo JA. Molecular, immune and microbial predictors of response and toxicity to combination immune checkpoint blockade (CICB) in melanoma (MEL) patients. Proceedings of SMR 2017, 11/2017.
57. Haymaker C, Uemura M, Hwu WJ, Murthy R, James M, Bhatta A, Bentebibel SE, Brevard J, Geib J, Lipford K, Cornfeld M, Chunduru S, Yee C, **Woodman SE**, Amaria R, Patel S, Tawbi H, Glitza IO, Davies M, Overwijk W, Hwu P, Bernatchez C, Diab A. TLR9 agonist harnesses innate immunity to drive tumor-infiltrating T cell expansion in distant lesions in a phase 1/2 study of intratumoral IMO-2125+ipilimumab in antiPD1 refractory melanoma patients. Journal for ImmunoTherapy of Cancer, Proceedings of SITC 2017:82 (#O18), 11/2017.
  58. Chattopadhyay C, Roszik J, Grimm EA, **Woodman SE**. Monosomy 3 uveal melanoma cells have a unique metabolic phenotype distinct from disomy 3. Investigative Ophthalmology & Visual Science 58 (8), Presented at ARVO Annual Meeting (2504), Baltimore, MD. 2017.
  59. Mitra A, Roh W, Reuben A, Macedo M, Carapeto FC, Gumbs C, Zhang J, **Woodman SE**, Hwu P, Hwu WJ, Lazar AJ, Wargo JA, Futreal PA. Multi-spatial whole-lesion molecular heterogeneity of an immunotherapy-resistant metastatic melanoma. Proceedings of ASCO Annual Meeting 2018 (#217967), 2018.
  60. Tawbi HA, Peng W, Milton D, Amaria RN, Glitza IC, Hwu WJ, Patel SP, Wong MKK, **Woodman SE**, Yee C, McQuade JL, Tetzlaff MT, Lazar AJ, Cain S, Burton EM, Beumer JH, Hwu P, Davies MA. Phase I/II Study of the PI3K $\beta$  Inhibitor GSK2636771 in Combination with Pembrolizumab (P) in Patients (pts) with PD-1 Refractory Metastatic Melanoma (MM) and PTEN Loss. Proceedings of ASCO Annual Meeting 2018 (#227367), 2018.
  61. Tawbi HA, Amaria RN, Glitza IC, Milton D, Hwu WJ, Patel SP, Wong MKK, Yee C, **Woodman SE**, Mcquade JL, Hwu P, Perdon KM, Shephard M, Burton EM, Wargo JA, Davies MA. Safety and Preliminary Activity Data From a Single Center Phase II Study of TRiPlet combination of Nivolumab (N) with Dabrafenib (D) and Trametinib (T) [TRIDeNT] in Patients (Pts) with BRAF-Mutated Metastatic Melanoma (MM). Proceedings of ASCO Annual Meeting (#228895), 2018.
  62. Chattopadhyay C, Roszik J, **Woodman SE**, Grimm EA. Monosomy 3 Uveal Melanoma Cells Have Altered Mitochondrial Activity. Presented at Keystone Symposia Meeting, Snowbird, UT. January 21-25, 2018.
  63. McKean MA, Oba J, Ma J, Haydu LE, Bassett Jr. RL, **Woodman SE**. Immune checkpoint inhibitor responses in KIT-mutated metastatic melanoma. Presented at ASCO-SITC Clinical Immuno-Oncology Symposium, San Francisco, CA. January 25-27, 2018.

#### Book Chapters

1. Margolin K, Sondak V, Swetter S, **Woodman SE**. Melanoma In: Holland-Frei Cancer Medicine, 9<sup>th</sup>, 2017. John Wiley & Sons, Inc. Editor Robert C. Bast Jr., Carlo M. Croce, William N. Hait, Waun Ki Hong, Donald W. Kufe, Martine Piccart-Gebhart, Raphael E. Pollock, Ralph R. Weichselbaum, Hongyang Wang and James F. Holland.
2. **Woodman SE**. KIT Kinase. Targeted Therapy in Translational Cancer Research, 2016. John Wiley & Sons, Inc. Editor Apostolia-Maria Tsimberidou, Razelle Kurzrock and Kenneth C. Anderson.

#### Books (edited and written)

N/A

#### Letters to the Editor

Yu X, Ambrosini G, Roszik J, Eterovic AK, Stempke-Hale K, Seftor EA, Chattopadhyay C, Grimm E, Carvajal RD, Hendrix MJ, Hodi FS, Schwartz GK, **Woodman SE**. Genetic Analysis of the 'Uveal Melanoma' C918 Cell Line Reveals Atypical BRAF and Common KRAS Mutations and Single Tandem Repeat Profile Identical to the Cutaneous Melanoma C8161 Cell Line. Pigment Cell & Melanoma Research 28(3):357-9, 5/2015. e-Pub 3/2015. PMID: 25515650.

#### Manuals, Teaching Aids, Other Teaching Publications

1. **Woodman SE**. Skin Cancer, Melanoma. In: Handbook of Targeted Cancer Therapy, 2014
2. **Woodman SE**. Skin Cancer, Melanoma. In: Handbook of Targeted Cancer Therapy, 2018

**Other Publications**

**Woodman SE.** A Characterization of Caveolins/Caveolae in Cardiac and Smooth Muscle Tissues. Ph.D. Thesis. Albert Einstein College of Medicine, New York, NY, 2004.

**EDITORIAL AND REVIEW ACTIVITIES**

**Editor/Service on Editorial Board(s)**

N/A

**Member of Editorial Review Board**

N/A

**Journal Reviewer**

Reviewer, Cancer Research, 2010-present

Reviewer, Clinical Cancer Research, 2010-present

Reviewer, Lancet, 2010-present

Reviewer, Journal of Investigative Dermatology, 2012-present

Reviewer, Pigmented Cell and Melanoma Research, 2012-present

Reviewer, JAMA Oncology, 2012-present

Reviewer, Nature Medicine, 2017-present

**Other Editorial and Review Activities**

Member of the Systems Biology and Convergence Section of the Bioinformatics and System Biology Subcommittee of the 2018 Program Committee. AACR Annual Meeting. Chicago, IL April 14-18, 2018

**TEACHING**

**Teaching Within Current Institution - The University of Texas MD Anderson Cancer Center**

**Formal Teaching**

**Courses Taught**

N/A

**Training Programs**

Lecturer, DoCM Medical Oncology Clinical Fellows, Melanoma Rotation, 2010-present

Lecturer, Department of Melanoma Medical Oncology, Clinical Fellows, 2010-present

**Other Formal Teaching**

Director, Melanoma Medical Oncology Grand Rounds, 2011-2017

Lecturer, "Molecular Underpinnings of Acral, Mucosal and Uveal Melanoma" Fellows Graduate Medical Education Lecture Series, 1/9/2012

Lecturer, DoCM Hematology/Oncology Fellows' Research Curriculum Series, 2/21/2017

**Supervisory Teaching**

**Committees**

**Advisory Committees**

Mentor, Faculty Advisory Committee, Instructor, Chandrani Chattopadhyay, PhD, 2010-2015

Mentor, Faculty Advisory Committee, Assistant Professor, Chandrani Chattopadhyay, PhD, 2015-present

Mentor, Graduate Candidacy Committee UT GSBS, Yan Yang, 2010-2013

Mentor, Graduate Candidacy Committee UT GSBS, Caitlin Creasy, 2016-present

Mentor, UT/MD Anderson MD/PhD Program, Deborah Silverman, 2017-present

**Supervisory Committees**

Mentor, Graduate Candidacy Committee UT GSBS, Yan Yang, 2010-2013

Mentor, Post-Doctoral Researcher, Amjad Talukder PhD, 2017-present

**Examining Committees**

Member, Graduate Candidacy Committee UT GSBS, Yan Yang, 2013

Member, Graduate Candidacy Committee UT GSBS, Brenda Melendez, 2013

**Direct Supervision**

**Undergraduate and Allied Health Students**

Research Supervisor, Shawn Gurwara, Rice University, 2009-2010

Research Supervisor, Brendan Hayes, Rice University, 2010-2011

Research Supervisor, Alexandra Ngo, 2012-2014

**Medical Students**

Research Supervisor, Katherine Roth, UT Medical School Houston, 2014-2016

**Graduate Students**

Research Supervisor, Ansu Antony, University of Houston Graduate School, 2010-2011

Co-Research Supervisor, Yan Yang, UT GSBS, 2010-2013

Co-Research Supervisor, Robert Szczepaniak Sloane, UT GSBS, 2016-present

Co-Research Supervisor, Akash Mitra, UT GSBS, 2017-present

**Postdoctoral Research Fellows**

Research Supervisor, Jahan Khalili, PhD, 2011-2013

Research Supervisor, Phuong Vo, MD, PhD, 2012-2014

Research Supervisor, Junna Oba MD, PhD, 2013-2016

**Clinical Residents and Fellows**

Research Supervisor, Meredith McKean, MD, Medical Oncology Fellow, 2016-present

**Other Supervisory Teaching**

Research Supervisor, Ryan Kwak, High School Student, 2010

Research Supervisor, Janos Roszik, PhD, Programmer Analyst I, 2012-2013

Research Supervisor, Janos Roszik, PhD, Senior Research Programmer, 2013-2015

Research Supervisor, Yan Li, MD, PhD, Visiting Scholar, 2014-2015

Research Supervisor, Chandrani Chattopadhyay, PhD, Instructor, 2010-2015

Research Supervisor, Chandrani Chattopadhyay, PhD, Assistant Professor, 2015-present

**Teaching Outside Current Institution**

**Formal Teaching**

**Courses Taught**

**Woodman SE.** Ocular Melanoma Foundation, 2011

**Woodman SE.** Scientific Advances and Clinical Trials in Ocular Oncology Course. ARVO Education Course, Fort Lauderdale, Florida May 3<sup>rd</sup>, 2012

**Woodman SE.** GNAQ/GNA11 and Beyond: Targeted Therapies and Implications for Clinical Trials, Cure OM Scientific Meeting, Fort Lauderdale, Florida, May 4<sup>th</sup>, 2012

**Woodman SE.** Ophthalmic Oncology Update: Molecular Signature of Ocular and Orbital Tumors and Targeted Biologic Treatment Opportunities, ARVO Education Course, Seattle, Washington, May 4<sup>th</sup>, 2013

**Training Programs**

N/A

**Other Formal Teaching**

**Woodman SE**, Melanoma Oncology APN Didactic Lectures, 2016-Present

**Supervisory Teaching**

**Committees**

**Advisory Committees**

N/A

**Supervisory Committees**

N/A

**Examining Committees**

N/A

**Direct Supervision**

**Undergraduate and Allied Health Students**

Graduate Instructor, Integrated Studies in the Arts and Humanities 231C, Michigan State University, Graduate students, 6/1995-6/1996

Instructor, Introductory Biology Lab, Yeshiva University, Biology students, 1/1998-2002

**Medical Students**

Clinical Instructor, Harvard Medical Student Core 1 & 2 Lecture Series, Harvard Medical School/BIDMC, 6/2005-6/2007

**Graduate Students**

N/A

**Postdoctoral Research Fellows**

N/A

**Clinical Residents and Fellows**

**Other Supervisory Teaching**

Graduate Assistant, Ethical Issues in Health Care, Michigan State University, Graduate students, 6/1993

Graduate Assistant, Integrated Studies in the Arts and Humanities 231A, Michigan State University, Graduate students, 1/1994-6/1995

Chief Medical Resident, Veteran's Administration Hospital, Harvard Medical School, Boston University Medical School, Medical students, 9/2006-11/2006

**CONFERENCES AND SYMPOSIA**

**Organization of Conferences/Symposia (Include chairing session)**

**Woodman SE**. Symposium Organizer and Session Chair, Emerging Issues in the Cancer Microenvironment Symposium, Cambridge, MA, 9/2012

**Woodman SE**. Session Chair, Translational Research in Uveal Melanoma, Cure OM Scientific Meeting, Society for Melanoma Research, Orlando, FL, May 2<sup>nd</sup>, 2014

**Woodman SE**. Session Chair, Novel Targets in Uveal Melanoma, Cure OM Scientific Meeting, Society for Melanoma Research, San Francisco, CA, November 21<sup>st</sup>, 2015

**Woodman SE**. Session Chair, Targeted Therapies for Uveal Melanoma, Cure OM Scientific Meeting, Society for Melanoma Research, Boston MA, November 1<sup>st</sup>, 2016

**Presentations at National or International Conferences**

**Invited**

**Woodman SE**, Targeting Genetic Aberrations in Uveal Melanoma. Investigative Ophthalmology & Visual Science 2010, 51(13): 869. (Presented at The Association for Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale, FL, 5/2/2010)

**Woodman SE**, GNAQ/11 Mutant Dependent Uveal Melanoma Sensitivity to MEK and PI3K Inhibitors. (Presented at The Association for Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale, FL, 5/1/2011)

**Woodman SE**, 2nd Annual Ocular Melanoma Scientific Working Group Symposium, October 22-23, 2010, Boston

**Woodman SE**. Treatment of Metastatic Uveal Melanoma, American Association of Ophthalmic Oncologists and Pathologists (AAOOP) Annual Meeting, Fort Lauderdale, FL, 5/2011

**Woodman SE**. GNAQ/11 Mutant Dependent Uveal Melanoma Sensitivity to MEK and PI3K Inhibitors., National Cancer Institute Translational Science Meeting, Washington, D.C., 7/2011

**Woodman SE** Treatment of Metastatic Uveal Melanoma. American Association of Ophthalmic Oncologists and Pathologists, Orlando, FL, 10/21/2011

**Woodman SE** GNAQ/11 Mutant-Dependent Uveal Melanoma: Sensitivity to MEK and PI3K Inhibition, International Society of Ocular Oncology (ISOO), Buenos Aires, Argentina, 11/14/2011

**Woodman SE**. KIT Mutations in Melanoma: Where Are We Now? AACR Annual Meeting, Chicago, IL, 03/2012.

**Woodman SE** Beyond GNAQ/GNA11. Melanoma Research Foundation (MRF) CureOM Scientific Meeting, Fort Lauderdale, FL 5/4/2012

**Woodman SE**. Targeted Therapy in Uveal Melanoma. Melanoma Research Foundation (MRF) Cure OM Eyes on a Cure Patient and Caregiver Symposium, Philadelphia, PA 6/16/2012

**Woodman SE**. TCGA Uveal Melanoma Project Update. International Society of Ocular Oncology (ISOO), Paris, France, 8/6/2015

**Woodman SE**. A novel algorithm applicable to cancer next generation sequencing panels accurately predicts total tumor mutation load and correlates with clinical outcomes in melanoma, GAP Young Investigator Workshop, Oslo, Norway, 8/2015

**Woodman SE** Stavanger University Hospital, Stavanger, Norway, 9/2015

**Woodman SE**, Global Academic Programs, A Medical Education Program on Melanoma Management, Spain, May 13, 2016

**Woodman SE**. Global Academic Programs, A Medical Education Program on Melanoma Management, Mexico, Nov 18, 2016

**Woodman SE**. Unraveling Uveal Melanoma with New Cell and *in vivo* Models. Melanoma Research Alliance (MRA) Ninth Annual Scientific Retreat; Washington DC, 2/2017

**Woodman SE**. Cancer Cell-Intrinsic Features of Response to Immune Therapies in Melanoma. 3<sup>rd</sup> Annual Immune Checkpoint Inhibitor Conference (ICI); Boston, MA. March 14-16, 2017

**Woodman SE**. Novel neoadjuvant targeted therapy trial yields insight into molecular mechanisms of response. Novel Agents and Interventions in Clinical Trials Session. AACR Annual Meeting, Washington DC, 4/2017

**Woodman SE**, Global Academic Programs, A Medical Education Program on Melanoma Management, Spain, Sep 28, 2017

#### **Other, Including Scientific Exhibitions**

N/A

### **Seminar Invitations from Other Institutions**

**Woodman SE.** CURE OM Round Table Discussion, Memorial Sloan-Kettering Cancer Center, New York City, November 16, 2012.

**Woodman SE.** The Molecular Biology of Uveal Melanoma, Grand Rounds Lecture, Jules Stein Eye Institute, University of California Los Angeles, Los Angeles, CA. November 14<sup>th</sup> 2012

**Woodman SE.** Translating Comprehensive, Integrated Molecular Analyses of Melanoma Subtypes to the Clinic. Thomas Jefferson University, Departments of Cancer Biology and Biochemistry & Molecular Biology Seminar Series, Philadelphia, PA. February, 16<sup>th</sup> 2016

**Woodman SE.** Comprehensive and Integrated Analysis of Uveal Melanoma. Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL. January 4-5<sup>th</sup>, 2018

### **Lectureships and Visiting Professorships**

N/A

### **Other Presentations at State and Local Conferences**

**Woodman SE.** Speaker, Institutional Grand Rounds, "KIT mutant melanoma" MD Anderson Cancer Center, Houston, TX, 11/2010

**Woodman SE.** and Esmaeli, B. CURE OM Eyes on a Cure: Patient and Caregiver Symposium Research Advances: Learn about the latest discoveries advancing the understanding and treatment of ocular melanoma, Houston, TX, March 2-3, 2013

**Woodman SE.** Mucosal and Ocular Melanoma – How Does Molecular Analysis Impact Management. The Art and Science of the New Melanoma Landscape: A Case-Based Multidisciplinary Approach, Houston, TX, September 27-28, 2013

**Woodman SE.** How Does Molecular Analysis Impact Management. The Art and Science of the Evolving Melanoma Landscape: A Case-Based Multidisciplinary Approach, Houston, TX, October 24-25, 2014

**Woodman SE.** Advances in Orbital Oncology and Oculofacial Plastic Surgery, MD Anderson Cancer Center, February 27-28, 2015

**Woodman SE.** Speaker, Tumor Mutation Load and Response to Immune Therapy. Melanoma Medical Oncology/Immunology Weekly Research Meeting. MD Anderson Cancer Center, April 13, 2015

**Woodman SE.** Session Chair and Speaker, Institutional Grand Rounds, "Uveal Melanoma - Knowns and Unknowns," MD Anderson Cancer Center, Houston, TX, 07/2015

**Woodman SE.** Mutations associated with primary meningeal and uveal melanoma. UTMB Health, 4th UTMB Brain Symposium, Galveston, TX, 9/2015

**Woodman SE.** Targeted Therapy for Melanoma: A Personalized Approach. AIM at Melanoma Foundation Patient Symposium, Houston, TX, May 21<sup>st</sup>, 2016

**Woodman SE.** Speaker, Update on Uveal Melanoma Biology. Melanoma Medical Oncology/Immunology Weekly Research Meeting. MD Anderson Cancer Center, January 25, 2016

**Woodman SE.** Uveal Melanoma SPORE Webinar, Uveal Melanoma Program – Bench to Bedside. February 9<sup>th</sup>, 2016

**Woodman SE.** Speaker, Cancer Cell-intrinsic Gene Expression Programs Correlate With Melanoma Clinical Outcome to Immunotherapy. Departments of Genomic Medicine and Cancer Biology Weekly Research Meeting. December 1, 2016



**Woodman SE.** Speaker, Cancer Cell Intrinsic Features of Immune Checkpoint Efficacy. Melanoma Medical Oncology/Immunology Weekly Research Meeting. MD Anderson Cancer Center, December 12, 2016

**Woodman SE.** Speaker, Division of Cancer Medicine Grand Rounds, "Cancer Cell-Intrinsic Features of Response to targeted and Immune Therapies in Melanoma," MD Anderson Cancer Center, Houston, TX, February 28, 2017

**Woodman SE.** Speaker, Integrative Omics Analysis Identified Key Modulators of Phenotypic Melanoma States. Melanoma Medical Oncology/Immunology Weekly Research Meeting. MD Anderson Cancer Center, March 26, 2018

## **PROFESSIONAL MEMBERSHIPS/ACTIVITIES**

### **Professional Society Activities, with Offices Held**

#### **National and International**

Beta Beta Beta (National Biology Honor Society)  
Member, 6/1991

Omicron Delta Kappa (National Leadership Honor Society)  
Member, 6/1991

Sigma Zeta (National Science and Mathematics Honor Society)  
Member, 6/1992

Phi Kappa Phi (National Academic Honor Society)  
Member, 6/1995

Physicians for Social Responsibility  
Member, 6/1997

Alpha Omega Alpha, Honor Medical Society  
Member, 6/2004

American Society of Clinical Oncology  
Member, 6/2009

Association for Research in Vision and Ophthalmology  
Member, 6/2010

Society for Melanoma Research  
Member, 9/2015

#### **Local/State**

Harris County Medical Society, Houston, TX  
Member, 1/2015

## **UNIQUE ACTIVITIES**

- Pathogenesis of Neuroimmunologic Disease Course, Marine Biological Lab, Woods Hole, MA, 07/1998
- Tropical Medicine Disease Medicine Rotation, Bach Mai Hospital, Hanoi, Vietnam, 04/1999
- Transitioning from Training to Faculty Course, Harvard Medical School, Boston, MA, Jan 29<sup>th</sup>, 2007
- Methods in Clinical Cancer Research Workshop, American Association of Cancer Research and American Society of Clinical Oncology, Vail, CO, 2008
- Molecular Biology in Clinical Oncology Workshop, American Association of Cancer Research, Aspen, CO, 2008
- Video Presenter, TalkAboutHealth - Answers from the World's Leading Medical Experts, Uveal Melanoma, 2012.

- Faculty Leadership Academy graduate (cohort 14), MD Anderson Cancer Center, Houston, TX. 2015

**DATE OF LAST CV UPDATE**

05/06/18